BIOMARKERS PREDICTING A THERAPEUTIC RESPONSE TO THERAPY WITH A CHIMERIC ANTIGEN RECEPTOR, AND USE THEREOF Russian patent published in 2021 - IPC G01N33/574 C12N5/783 A61P35/02 

FIELD: medicine; oncology.

SUBSTANCE: group of inventions can be used to assess or monitor the effectiveness of therapy in an individual having a hematologic malignant tumor. Method for assessing the clinical effectiveness of CAR19-expressing cells in an individual having a haematological malignant tumor, involves obtaining a CD27+ CD45RO− immune effector cell level in a population of CD8+ T-cells in a sample obtained from an individual, or in a sample of a product containing a population of CAR19-expressing cells. Higher percentage of CD27+ CD45RO− immune effector cells in the CD8+ population compared to the number of CD27+ CD45RO− immune effector cells in the non-responding individual indicates that individual responds to therapy with CAR19-expressing cells. Group of inventions also relates to a method of treating a hematologic malignant tumor in an individual, comprising administering a CAR19-expressing cell product to an individual, as well as a method of evaluating the CAR19-expressing cell product efficiency.

EFFECT: use of this group of inventions enables evaluating the effectiveness of therapy with CAR19-expressing cells, where complete remission in CLL patients with CART19 immunotherapy is associated with higher amounts of infused CD27+ PD1− CART cells.

19 cl, 23 dwg, 24 tbl, 7 ex